A stabilized mRNA carrier turns tumor injection into broader immune activation by extending vaccine delivery to lymph nodes and the spleen.
(Nanowerk Spotlight) A cancer vaccine injected into a tumor would seem to have reached the right address. The tumor is where malignant cells are growing, where immune cells need help, and where local suppression can blunt an attack. But a tumor is not where the immune system does all its learning. Some of the most important decisions happen in lymph nodes and the spleen, where immune cells learn what to attack, multiply, and form memory.
That creates a delivery problem. A vaccine placed inside a tumor must do more than stay there. It has to activate immune cells in the hostile tumor environment while also carrying its message to the organs that train longer-lasting defenses. If the message remains too local, the response may fade. If the carrier breaks apart too soon, the message may never reach cells that can amplify it.
Messenger RNA can supply that message directly by encoding tumor markers or immune-activating proteins. Yet mRNA is fragile, and its effect depends heavily on the particle that protects and transports it. For in situ cancer vaccination, the carrier has to perform a difficult balancing act: remain stable after local injection, protect its cargo in biological fluids, and release it inside the right immune cells.
The proposed in situ mRNA cancer vaccine uses a double-branched lipopolymer nanoparticle to stabilize and deliver mRNA after intratumoral injection. The carrier protects mRNA encoding a tumor antigen and IL-12, allowing expression both in the tumor microenvironment and in peripheral lymphoid organs. This dual-site delivery is designed to activate antigen-presenting cells, promote T cell priming, reprogram local immune suppression, and support longer-lasting anti-tumor immunity. (Image: Reproduced with permission from Wiley-VCH Verlag) (click on image to enlarge)
The platform centers on a molecule called P6CIT. It combines a branched polymer head with branched lipid tails, giving the carrier a tightly packed internal structure. That detail matters because nanoparticle stability depends partly on how freely its internal chains can move. When those chains move too freely, the particle can become easier to disrupt. Restricting that motion helps the carrier hold together in biological fluids.
The researchers tested that design by comparing P6CIT with a related particle that lacked the same double-branched structure. P6CIT showed higher internal viscosity, greater stiffness, better stability in serum, and stronger protection of encapsulated mRNA. Those material changes translated into a different biodistribution pattern in animals, where the stabilized particle carried mRNA activity farther from the injection site.
The difference appeared most clearly in distal immune tissues. P6CIT produced only a modest increase in mRNA expression where it entered the body, compared with the less stable particle. In immune organs, the gain was much larger, with 6.9-fold higher expression in lymph nodes and 13.6-fold higher expression in the spleen. The carrier’s stability helped mRNA activity extend beyond the tumor.
This focus on carrier design fits a wider shift in RNA medicine. Researchers increasingly treat polymer and lipid nanoparticles as active parts of therapy, not as interchangeable packaging. Nanowerk has previously covered redesigned lipid nanoparticles that get more mRNA working inside cells, a related effort to improve how RNA carriers behave after entering cells. In the new work, the key improvement came earlier, by keeping the carrier intact during transport.
The next test was whether the mRNA reached immune cells able to use it. After intratumoral injection in melanoma-bearing mice, the particles produced mRNA expression in tumors, draining lymph nodes, and the spleen. They favored antigen-presenting cells such as macrophages and dendritic cells. These cells act as immune instructors, showing T cells what a threat looks like and helping set the strength of the response.
The therapeutic version of the vaccine carried two mRNA payloads. One encoded a tumor antigen, which gave the immune system a cancer-associated target. The other encoded IL-12, an immune-activating protein that can push suppressed immune environments toward a more inflammatory state. The pairing addressed both sides of the problem: recognition of the tumor and reversal of local immune suppression.
Route of administration mattered. When the researchers compared intratumoral, intramuscular, and subcutaneous injection, the intratumoral route produced stronger immune activation inside tumors. Tumor samples showed increased signs of dendritic cells, macrophages, CD8⁺ T cells, and interferon-γ, a signaling molecule associated with anti-cancer immune activity. The result supported the logic of treating the tumor as both disease site and immune-activation site.
The response involved several immune compartments rather than a single cell type. The combined antigen and IL-12 vaccine shifted macrophages away from an immunosuppressive M2-like state and toward a more inflammatory M1-like state. It also increased markers of cytotoxic T cell activity and natural killer cell activation. These immune shifts provided the rationale for testing whether the formulation could control established melanoma.
Therapeutic testing used mouse melanoma models. In a B16-OVA model, a single intratumoral dose of the combined vaccine produced complete tumor regression in 42.9% of treated mice. Antigen mRNA alone did not provide comparable control. IL-12 mRNA alone delayed tumor growth, but most tumors returned. The combined treatment worked better because it paired tumor targeting with immune reprogramming.
The researchers also asked whether tumor clearance produced immune memory. Mice that cleared their tumors resisted later rechallenge with the same melanoma model, including a test designed to examine lung metastasis. Their antigen-specific memory T cells responded after rechallenge, indicating that the treatment did more than shrink the original tumor. It left behind immune cells prepared to respond again.
A repeated low-dose schedule improved the effect in the same model. Three intratumoral doses of 2.0 µg each produced sustained tumor suppression and 100% survival at the study endpoint. Single-component treatments delayed tumor growth but did not prevent recurrence. That result suggests the platform may benefit from dosing that maintains immune pressure rather than relying on one larger intervention.
The team then moved beyond the model OVA antigen to a wild-type B16F10 melanoma model using TRP2, a melanoma-associated antigen. The P6CIT vaccine controlled tumors better than a comparable formulation based on ALC-0315, a clinically important ionizable lipid used in mRNA vaccine technology. That comparison strengthened the case that structural stabilization, not only the choice of mRNA cargo, drove the improved response.
Safety data remained limited to animal testing, but the early signs were favorable. At the tested therapeutic dose, tissue analysis of the heart, liver, spleen, lungs, and kidneys showed no obvious tissue damage. Blood markers associated with liver and kidney function stayed within baseline ranges. These findings do not establish clinical safety, but they support further preclinical work on the formulation.
The study still faces practical questions. Intratumoral injection works best for tumors that clinicians can reach safely. Human tumors also vary more than mouse tumors in antigen diversity, immune suppression, and treatment history. Manufacturing a defined lipopolymer formulation at clinical scale would require additional development. The results therefore point to a design strategy, not a ready clinical therapy.
The central advance is that nanoparticle architecture changed the reach of an mRNA cancer vaccine. By stabilizing the carrier through double-branched lipopolymer chemistry, the researchers connected local tumor treatment with immune training in lymphoid organs.
Alongside related work on mRNA cancer vaccines that report when they start working, the study points toward a clear design principle: carrier chemistry can determine whether a local mRNA vaccine remains local or becomes a coordinated immune intervention.
For authors and communications departmentsclick to open
Lay summary
Prefilled posts
Nanowerk Newsletter
Get our Nanotechnology Spotlight updates to your inbox!
Thank you!
You have successfully joined our subscriber list.
Become a Spotlight guest author! Join our large and growing group of guest contributors. Have you just published a scientific paper or have other exciting developments to share with the nanotechnology community? Here is how to publish on nanowerk.com.
